Hot Investor Mandate: Global Investment Firm Deploys Up to $15M in Private and Public Companies, With Strong Interests in Oncology, Cardiovascular, Metabolic Diseases, Etc.

8 Oct

A global healthcare and life science company drives value in private and public companies through operational and strategic direction as well as patient capital. The firm is headquartered in Western Europe and has an additional office in the USA. Given its structure and source of capital, the firm can acquire interests in early and late stage ventures without restriction on the location of opportunities. As a public company, the firm is a source of permanent capital. Average initial stakes range from $5M – $15M in the form of equity, with additional capital reserved for follow-on investments, The firm prefers to have a Board position in order to actively support the companies in which it invests.

The firm is focused on areas of unmet medical need, strongly favoring breakthrough and cutting-edge technologies over iterative or symptomatic treatments. The firm has particular interests in oncology (especially immuno-oncology), cardiovascular, metabolic, neuroscience indications, anti-infectives, gene therapy, and orphan diseases, as well as other therapeutic areas. The firm invests across the life cycle of development, from company formation through to companies with marketed products.

The firm is open to working with a variety of companies and entrepreneurs, but prefers management teams who have prior experience in the specific stage of development (clinical development, commercial strategy, etc.) and indication/area of their current venture. The firm also looks for startups companies with a strong BOD, SAB and support network (legal, back office, KOLs, etc.), though these are not prerequisites.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm With Global Offices Invests Up to $10M in Therapeutics and Medical Devices, Open to All Subsectors and Indications

8 Oct

An investment firm with offices in USA, Western Europe, and India, is actively seeking investment and partnership opportunities with therapeutics and medical device companies across the globe. In addition, the firm is interested in nutraceuticals and cosmeceuticals. Typical size of initial investment is around $5M, though the firm is capable of investing up to $10M and this is largely dependent on a case-by-case. The firm is capable of funding up to ~40% of the required amount for late stage clinical trials. The firm is also interested in-licensing partnerships and seek licensing and marketing rights on opportunities in which the firm can add significant value.

Within therapeutics and medical devices, the firm is generally sector and indication agnostic. The firm is focused on later-stage opportunities with a low risk profile, usually companies in Phase IIb and beyond. However, the firm is very keen to speaking with earlier stage opportunities that demonstrate strong clinical data and high potential to enter the global market and building a long-term relationship with these groups. In terms of medical devices, the firm will invest in near market ready products. The firm generally does not invest in diagnostics or digital health.

The firm seeks to invest in companies with experienced management teams with domain expertise, strong clinical data, and a clear exit strategy. The firm has an extensive professional network including fellow investors, high net worth individuals, clinical trial/regulatory affairs partners, etc. The firm takes a very active role in supporting their portfolio companies and provides mentorship and support on regulatory issues, market access, and effective clinical development strategies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Wealth Firm Invests in Early-Stage Medical Device and Digital Health Companies, Open to Global Opportunities as Early as Pre-Prototype

8 Oct

A private wealth investment firm invests globally in medically related early-stage companies. Initial size of investment largely varies depending on the deal’s stage of development and other involved investors.

The firm invests in medtech and digital health companies. The firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements. While the firm generally co-invests alongside a syndicate, the firm has led a financing before and is open to acting as the lead investor if the firm determines that they could add significant value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Canadian Firm Interested In Medical Devices & Diagnostics Companies With Large Social Impact, Investing Early as Conceptual Stages of Development

8 Oct

A venture philanthropy firm located in Canada seeks to fund diagnostics and medical device companies that have a large social impact. The firm looks to invest early, even during conceptual stages. The firm’s main focus is on the entrepreneur. The firm typically invests between $2.5 million to $5 million in one company per year and remains highly involved throughout the development of the company. The firm will consider investing in companies located in North America.

The firm is interested in companies within the medical device or diagnostics space. The firm is both subsector and indication agnostic, looking instead at the social impact of the technology. Previous investments include two in vitro cancer diagnostics companies and a company developing a novel treatment for major depressive disorder. The firm will not consider investing in therapeutics.

The firm funds entrepreneurs first and ideas second. The firm looks for driven entrepreneurs and invests in them.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Interview with Life Science Nation CEO, Dennis Ford on Longevity, Health & Innovation Conference

1 Oct

By Rory McCann, Marketing Manager & Conference Producer, LSN

Rory McCann (RM): This year, so many conferences have gone virtual or have been cancelled, but you’ve released a new conference: 4D Meets AI, and announced a new one: Longevity, Health & Innovation. Why are you expanding on your flagship conference, RESI?

Dennis Ford (DF): Basically, the market needed Life Science Nation (LSN) to expand so we can all get on with conducting the business of early-stage funding, partnerships and alliances. LSN sees its global investor network investing every week. LSN events have seen a 30% increase in attendees, and our digital events have turned into global digital events with meetings taking place 24-hours per day over 3 days straight. Our RESI September event had 1,500 virtual meetings in 3 days. Unfortunately, it looks like the planet has at least another year of this virtual reality to deal with and LSN is a vehicle for our clients to continue their invaluable work.

Regardless of the C-19 troubles, we are in the golden age of life science technology across the silos of drugs, devices, diagnostics, and digital health. There are literally tens of thousands of early-stage healthcare start-ups with a myriad of ground-breaking, game-changing, nascent technology surfacing all around the planet. To net it out, I am seeing compelling new products and services that are well-articulated with data and prototypes in-hand to show they can make a difference in the standard of care across the entire healthcare arena.

It used to be 10% of early-stage companies might have a chance to secure series A and make it to that 5-year milestone. At LSN RESI conferences, we see 3,000 early-stage companies each year going after seed, series A and B funding with an equal number of qualified investors looking to add to their portfolios. When we looked out on the horizon, AI and Longevity products and services seemed poised to make a huge impact. AI and Longevity will be the two beacons where this new technology is moving ahead at full speed. The early-stage technology is there, the investors are there, and LSN knows how to gather up the buyers and sellers with our unique partnering theme, so we said, “Let’s go for it!”

RM: What does Longevity, Health & Innovation have to add to the early stage partnering landscape? What will attendees get out of it that is unique compared to other partnering conferences, even RESI?

DF: There is a myriad of major diseases that affect the boomer generation, ranging from Alzheimer’s, Diabetes, and Cancer to Arthritis, Depression, and Diseases of the Eye and Heart. There are thousands of governmental and academic entities conducting research and helping translate the research into products and services that will have an impact on these debilitating illnesses. LSN sees all these companies at our RESI conferences and it became obvious to us that we needed to have a dedicated partnering and funding event that could cater to the Longevity and Health Innovation arena.

RM: You’ve partnered with Mary Furlong & Associates. What does that partnership offer to the success of the conference?

DF: Mary is the leader with her Longevity conference series that assembles all the major stakeholders together and creates a discussion and exchange of ideas regarding Longevity and Health. When LSN looked at the Longevity and Health landscape, it was evident that if we could bring Mary’s stakeholders and content, and LSN could bring our early-stage technology companies and global investors, we could broaden and enhance each other’s conferences. Mary produces high-quality content and LSN’s partnering system is exemplary; these two strengths make us very complementary. I believe that our quarterly, international, joint Longevity, Health & Innovation Conference will be the go-to Longevity global event.

Sign up for Longevity, Health & Innovation and save $150 on the super early bird rate until October 10!

The Innovator’s Pitch Challenge at Digital RESI

1 Oct

By Karen Deyo, Senior Investor Research Analyst, LSN

Participating in pitching events is a mainstay for start-ups looking to hone their pitches and attract investor attention. These events are beneficial, not only to gain exposure, but also as an exercise to find what works and what doesn’t in your messaging. Do panelists consistently ask the same questions? Are some parts of your value proposition unclear? Nothing hones your message better than lots of practice and doing so may end up improving your percentage of investor follow-ups after the initial meeting.

The Innovator’s Pitch Challenge at Digital RESI is an opportunity for early-stage companies to pitch directly to a panel of relevant investors and participate in a live Q&A session. For a $500 fee, accepted companies receive a dedicated page on the Digital RESI Live Agenda, with their pitch video prominently displayed for maximum exposure. Additionally, the Q&A sessions are livestreamed during Digital RESI, with all 300+ RESI investor attendees invited to join the audience.

We recommend that you apply soon! Applications are accepted on a rolling basis, and spots fill up fast.

4D Meets AI is Back January 14-15, 2021!

1 Oct

By Rory McCann, Marketing Manager & Conference Producer, LSN

The digital partnering conference connecting drugs, devices, diagnostics & digital health (4Ds) through the power of artificial intelligence (AI) is returning as part of the Life Science Nation (LSN) Healthtech Partnering Week, featuring three digital partnering events tackling different areas of the early-stage life science and healthcare arena. The previous 4D Meets AI saw more than 100 investors meet and network with over 150 early-stage companies, and we’re expecting bigger and better in January!

In life science and healthcare, AI solutions are increasingly becoming the standard, rather than a shiny new feature. Therefore, it is necessary to highlight specific challenges, as well as showcase successful tactics for investors and early-stage companies to learn from and grow.

Sign up at the super early bird rate and save $150 on registration. Don’t miss the opportunity to see the latest advancements in life science and health care and meet with the investors and strategic partners on the cutting edge of AI. Learn more at www.4dmeetsai.com.

← Older Entries
Newer Entries →